ABBVIE SWOT ANALYSIS TEMPLATE RESEARCH
Dive Deeper Into the Company's Strategic Blueprint
AbbVie's powerhouse portfolio-anchored by Humira and rapidly expanding oncology and aesthetics franchises-delivers robust cash flow but faces patent cliffs and pricing pressures; our full SWOT unpacks competitive moats, regulatory risks, and pipeline catalysts to inform strategic action. Purchase the complete SWOT to get an editable, investor-ready Word and Excel package with actionable recommendations.
Strengths
Skyrizi and Rinvoq combined annual revenue exceeding $17 billion
Skyrizi and Rinvoq together generated over $17 billion in 2025 revenue, effectively replacing Humira's decline and proving AbbVie's immunology transition works.
Skyrizi now holds leading shares in psoriasis and Crohn's-Skyrizi sales rose ~20% year-over-year to $9.8 billion in 2025-driving margin strength.
Rinvoq, with 2025 sales of about $7.4 billion, dominates the JAK market across RA, atopic dermatitis, and psoriatic arthritis.
The rapid uptake of both keeps AbbVie a high-margin immunology powerhouse through the decade, supporting free cash flow and EPS resilience.
Dominant 68 percent market share in the US medical aesthetics category
Through the Allergan acquisition, AbbVie controls top aesthetics brands Botox Cosmetic and Juvéderm, underpinning a dominant 68% US market share in medical aesthetics as of 2025 and driving roughly $7.4 billion in aesthetics revenue in FY2025.
This cash-pay segment is less exposed to government pricing pressure than AbbVie's pharma business, contributing stable, higher-margin cash flows (aesthetics gross margin ~65% in 2025).
Botox's strong brand loyalty creates a durable moat versus lower-cost neurotoxin entrants, with repeat-treatment frequency and patient recognition keeping unit volumes resilient.
Robust operating cash flow totaling approximately $22.5 billion annually
AbbVie generated roughly $22.5 billion in operating cash flow for fiscal 2025, funding R&D spend of about $6.1 billion while returning $7.8 billion to shareholders via dividends and buybacks.
Successful integration of the $10.1 billion ImmunoGen acquisition
AbbVie's $10.1 billion ImmunoGen buy gave it Elahere, a first-in-class ADC for ovarian cancer now posting $420 million in 2025 sales, beating initial forecasts and accelerating oncology revenue growth.
The deal strengthens AbbVie's oncology pipeline-ImmunoGen assets lift late-stage candidates to five from two-addressing prior analyst skepticism and showing management can execute large M&A to shift reliance from immunology.
- Acquisition price: $10.1 billion
- Elahere 2025 sales: $420 million
- Late-stage oncology candidates: 5 (up from 2)
- Strategic impact: diversifies revenue away from immunology
Status as a Dividend Aristocrat with 54 consecutive years of increases
AbbVie's 54-year dividend increase streak (Dividend Aristocrat) makes it a go-to for income investors; the company paid $6.96 per share in dividends in FY2025, yielding ~4.3% on a $162 share price (Mar 2026), underpinning a valuation floor amid biotech volatility.
Even through Humira's patent cliff, AbbVie grew dividends-operating cash flow was $16.2bn in FY2025-showing confidence in recurring earnings and buybacks that stabilize returns versus peers.
- 54 consecutive years of raises; $6.96 dividend in FY2025
- Dividend yield ~4.3% on $162 share (Mar 2026)
- FY2025 operating cash flow $16.2bn
- Provides valuation floor vs. volatile biotech peers
BMS 2025: Skyrizi/Rinvoq $17B, $22.5B OCF, $6.96 div - aesthetics $7.4B
Skyrizi + Rinvoq drove >$17B in 2025, replacing Humira; Skyrizi $9.8B (+20% YoY), Rinvoq $7.4B. Aesthetics (Botox/Juvéderm) ~68% US share, $7.4B revenue, ~65% gross margin. FY2025 operating cash flow $22.5B; dividends $6.96/share (yield ~4.3% on $162). Elahere $420M; ImmunoGen deal $10.1B.
| Metric | 2025 Value |
|---|---|
| Skyrizi | $9.8B |
| Rinvoq | $7.4B |
| Aesthetics | $7.4B (68% US) |
| Op. Cash Flow | $22.5B |
| Dividend | $6.96/share |
| Elahere | $420M |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of AbbVie, outlining its core strengths, operational weaknesses, near-term growth opportunities, and external threats shaping its competitive and financial trajectory.
Customizable Excel Spreadsheet
Provides a concise AbbVie SWOT snapshot to quickly highlight drug pipeline strengths, patent risks, market opportunities, and competitive threats for fast, board-ready strategy alignment.
Weaknesses
Humira revenue erosion exceeding 45 percent in the US market
Humira US revenue plunged over 45% in FY2025 to about $6.2 billion, as biosimilars captured major formulary share; this loss of exclusivity remains a drag on AbbVie's total top-line growth.
AbbVie has mitigated some impact via immunology and oncology launches, but replacing a >$5B annual decline requires flawless execution elsewhere to keep growth flat to positive.
Investors watch quarterly pace closely: any slower recovery or market-share erosion could spike downside to consensus estimates and share price volatility.
Total long-term debt load remaining near $60 billion
AbbVie carries roughly $60 billion of long-term debt as of FY2025, largely from the Allergan (2019) and Cerevel (2024) deals, and is actively deleveraging.
Higher interest rates in 2025 raise refinancing costs, forcing about $6-7 billion of annual cash flow toward interest and principal, reducing reinvestment capacity.
This leverage constrains AbbVie's ability to pursue mega-mergers near term, capping deal size unless equity or asset sales reduce debt materially.
Heavy concentration risk with three products representing 55 percent of sales
AbbVie's revenue remains concentrated: Skyrizi, Rinvoq and Botox accounted for about 55% of 2025 net revenues, leaving financial health tightly linked to those three brands.
Any regulatory setback or safety signal for Skyrizi (IL-23), Rinvoq (JAK) or Botox would likely cause outsized stock volatility given their revenue weight.
The company lacks a deep long-tail of mid-sized products, so targeted competition against these three drugs would materially erode margins and growth.
Significant reliance on the US market for 77 percent of net revenue
AbbVie earns 77% of net revenue from the US (2025 fiscal year: $38.6bn of $50.2bn), so US drug-pricing reforms or Medicare negotiation hit revenue hard.
That concentration makes AbbVie a clear target for domestic pricing and legislative shifts, unlike more diversified pharma peers.
Expanding international sales is tough: foreign pricing, lower margins, and faster biosimilar penetration reduce upside abroad.
- 77% US revenue in 2025 = $38.6bn of $50.2bn
- High exposure to US pricing reforms and Medicare negotiation
- International diversification limited by pricing and biosimilar pressure
FDA black box warnings on the JAK inhibitor class affecting Rinvoq
FDA black box warnings on JAK inhibitors curb Rinvoq uptake: post-2023 warnings tying JAKs to increased MACE (major adverse cardiovascular events) and malignancy risks limit Rinvoq as first-line therapy in rheumatoid arthritis and atopic dermatitis, lowering addressable market share versus biologics.
These safety flags force AbbVie into intensive physician education and REMS-like monitoring, raising commercial costs; Rinvoq US net sales were $5.6bn in FY2025 but growth slowed to 8% YoY amid class scrutiny.
The regulatory friction opened doors for TNF and IL-targeting biologics and newer oral TYK2 inhibitors, letting competitors capture switching and new-patient segments.
- FDA black box: links to MACE and cancer (post-2023)
- Rinvoq FY2025 US net sales $5.6bn; growth +8% YoY
- Higher marketing/compliance spend; constrained first-line use
- Biologics and TYK2 entrants gaining market share
AbbVie hit by Humira collapse, $60B debt and product concentration risk
Humira US sales fell ~45% in FY2025 to $6.2bn, leaving a >$5bn annual gap; AbbVie carries ~$60bn long-term debt and paid $6-7bn/year in interest/principal, limiting M&A and reinvestment; Skyrizi, Rinvoq and Botox made ~55% of 2025 revenue ($27.6bn of $50.2bn), raising concentration risk; Rinvoq US sales $5.6bn (FY2025) but growth slowed to +8% amid JAK safety warnings.
| Metric | FY2025 |
|---|---|
| Total revenue | $50.2bn |
| US revenue | $38.6bn (77%) |
| Humira US | $6.2bn (-45%) |
| Rinvoq US | $5.6bn (+8%) |
| Long-term debt | ~$60bn |
What You See Is What You Get
AbbVie SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality.
The preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.
ABBVIE SWOT ANALYSIS TEMPLATE RESEARCH
Dive Deeper Into the Company's Strategic Blueprint
AbbVie's powerhouse portfolio-anchored by Humira and rapidly expanding oncology and aesthetics franchises-delivers robust cash flow but faces patent cliffs and pricing pressures; our full SWOT unpacks competitive moats, regulatory risks, and pipeline catalysts to inform strategic action. Purchase the complete SWOT to get an editable, investor-ready Word and Excel package with actionable recommendations.
Strengths
Skyrizi and Rinvoq combined annual revenue exceeding $17 billion
Skyrizi and Rinvoq together generated over $17 billion in 2025 revenue, effectively replacing Humira's decline and proving AbbVie's immunology transition works.
Skyrizi now holds leading shares in psoriasis and Crohn's-Skyrizi sales rose ~20% year-over-year to $9.8 billion in 2025-driving margin strength.
Rinvoq, with 2025 sales of about $7.4 billion, dominates the JAK market across RA, atopic dermatitis, and psoriatic arthritis.
The rapid uptake of both keeps AbbVie a high-margin immunology powerhouse through the decade, supporting free cash flow and EPS resilience.
Dominant 68 percent market share in the US medical aesthetics category
Through the Allergan acquisition, AbbVie controls top aesthetics brands Botox Cosmetic and Juvéderm, underpinning a dominant 68% US market share in medical aesthetics as of 2025 and driving roughly $7.4 billion in aesthetics revenue in FY2025.
This cash-pay segment is less exposed to government pricing pressure than AbbVie's pharma business, contributing stable, higher-margin cash flows (aesthetics gross margin ~65% in 2025).
Botox's strong brand loyalty creates a durable moat versus lower-cost neurotoxin entrants, with repeat-treatment frequency and patient recognition keeping unit volumes resilient.
Robust operating cash flow totaling approximately $22.5 billion annually
AbbVie generated roughly $22.5 billion in operating cash flow for fiscal 2025, funding R&D spend of about $6.1 billion while returning $7.8 billion to shareholders via dividends and buybacks.
Successful integration of the $10.1 billion ImmunoGen acquisition
AbbVie's $10.1 billion ImmunoGen buy gave it Elahere, a first-in-class ADC for ovarian cancer now posting $420 million in 2025 sales, beating initial forecasts and accelerating oncology revenue growth.
The deal strengthens AbbVie's oncology pipeline-ImmunoGen assets lift late-stage candidates to five from two-addressing prior analyst skepticism and showing management can execute large M&A to shift reliance from immunology.
- Acquisition price: $10.1 billion
- Elahere 2025 sales: $420 million
- Late-stage oncology candidates: 5 (up from 2)
- Strategic impact: diversifies revenue away from immunology
Status as a Dividend Aristocrat with 54 consecutive years of increases
AbbVie's 54-year dividend increase streak (Dividend Aristocrat) makes it a go-to for income investors; the company paid $6.96 per share in dividends in FY2025, yielding ~4.3% on a $162 share price (Mar 2026), underpinning a valuation floor amid biotech volatility.
Even through Humira's patent cliff, AbbVie grew dividends-operating cash flow was $16.2bn in FY2025-showing confidence in recurring earnings and buybacks that stabilize returns versus peers.
- 54 consecutive years of raises; $6.96 dividend in FY2025
- Dividend yield ~4.3% on $162 share (Mar 2026)
- FY2025 operating cash flow $16.2bn
- Provides valuation floor vs. volatile biotech peers
BMS 2025: Skyrizi/Rinvoq $17B, $22.5B OCF, $6.96 div - aesthetics $7.4B
Skyrizi + Rinvoq drove >$17B in 2025, replacing Humira; Skyrizi $9.8B (+20% YoY), Rinvoq $7.4B. Aesthetics (Botox/Juvéderm) ~68% US share, $7.4B revenue, ~65% gross margin. FY2025 operating cash flow $22.5B; dividends $6.96/share (yield ~4.3% on $162). Elahere $420M; ImmunoGen deal $10.1B.
| Metric | 2025 Value |
|---|---|
| Skyrizi | $9.8B |
| Rinvoq | $7.4B |
| Aesthetics | $7.4B (68% US) |
| Op. Cash Flow | $22.5B |
| Dividend | $6.96/share |
| Elahere | $420M |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of AbbVie, outlining its core strengths, operational weaknesses, near-term growth opportunities, and external threats shaping its competitive and financial trajectory.
Customizable Excel Spreadsheet
Provides a concise AbbVie SWOT snapshot to quickly highlight drug pipeline strengths, patent risks, market opportunities, and competitive threats for fast, board-ready strategy alignment.
Weaknesses
Humira revenue erosion exceeding 45 percent in the US market
Humira US revenue plunged over 45% in FY2025 to about $6.2 billion, as biosimilars captured major formulary share; this loss of exclusivity remains a drag on AbbVie's total top-line growth.
AbbVie has mitigated some impact via immunology and oncology launches, but replacing a >$5B annual decline requires flawless execution elsewhere to keep growth flat to positive.
Investors watch quarterly pace closely: any slower recovery or market-share erosion could spike downside to consensus estimates and share price volatility.
Total long-term debt load remaining near $60 billion
AbbVie carries roughly $60 billion of long-term debt as of FY2025, largely from the Allergan (2019) and Cerevel (2024) deals, and is actively deleveraging.
Higher interest rates in 2025 raise refinancing costs, forcing about $6-7 billion of annual cash flow toward interest and principal, reducing reinvestment capacity.
This leverage constrains AbbVie's ability to pursue mega-mergers near term, capping deal size unless equity or asset sales reduce debt materially.
Heavy concentration risk with three products representing 55 percent of sales
AbbVie's revenue remains concentrated: Skyrizi, Rinvoq and Botox accounted for about 55% of 2025 net revenues, leaving financial health tightly linked to those three brands.
Any regulatory setback or safety signal for Skyrizi (IL-23), Rinvoq (JAK) or Botox would likely cause outsized stock volatility given their revenue weight.
The company lacks a deep long-tail of mid-sized products, so targeted competition against these three drugs would materially erode margins and growth.
Significant reliance on the US market for 77 percent of net revenue
AbbVie earns 77% of net revenue from the US (2025 fiscal year: $38.6bn of $50.2bn), so US drug-pricing reforms or Medicare negotiation hit revenue hard.
That concentration makes AbbVie a clear target for domestic pricing and legislative shifts, unlike more diversified pharma peers.
Expanding international sales is tough: foreign pricing, lower margins, and faster biosimilar penetration reduce upside abroad.
- 77% US revenue in 2025 = $38.6bn of $50.2bn
- High exposure to US pricing reforms and Medicare negotiation
- International diversification limited by pricing and biosimilar pressure
FDA black box warnings on the JAK inhibitor class affecting Rinvoq
FDA black box warnings on JAK inhibitors curb Rinvoq uptake: post-2023 warnings tying JAKs to increased MACE (major adverse cardiovascular events) and malignancy risks limit Rinvoq as first-line therapy in rheumatoid arthritis and atopic dermatitis, lowering addressable market share versus biologics.
These safety flags force AbbVie into intensive physician education and REMS-like monitoring, raising commercial costs; Rinvoq US net sales were $5.6bn in FY2025 but growth slowed to 8% YoY amid class scrutiny.
The regulatory friction opened doors for TNF and IL-targeting biologics and newer oral TYK2 inhibitors, letting competitors capture switching and new-patient segments.
- FDA black box: links to MACE and cancer (post-2023)
- Rinvoq FY2025 US net sales $5.6bn; growth +8% YoY
- Higher marketing/compliance spend; constrained first-line use
- Biologics and TYK2 entrants gaining market share
AbbVie hit by Humira collapse, $60B debt and product concentration risk
Humira US sales fell ~45% in FY2025 to $6.2bn, leaving a >$5bn annual gap; AbbVie carries ~$60bn long-term debt and paid $6-7bn/year in interest/principal, limiting M&A and reinvestment; Skyrizi, Rinvoq and Botox made ~55% of 2025 revenue ($27.6bn of $50.2bn), raising concentration risk; Rinvoq US sales $5.6bn (FY2025) but growth slowed to +8% amid JAK safety warnings.
| Metric | FY2025 |
|---|---|
| Total revenue | $50.2bn |
| US revenue | $38.6bn (77%) |
| Humira US | $6.2bn (-45%) |
| Rinvoq US | $5.6bn (+8%) |
| Long-term debt | ~$60bn |
What You See Is What You Get
AbbVie SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality.
The preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Dive Deeper Into the Company's Strategic Blueprint
AbbVie's powerhouse portfolio-anchored by Humira and rapidly expanding oncology and aesthetics franchises-delivers robust cash flow but faces patent cliffs and pricing pressures; our full SWOT unpacks competitive moats, regulatory risks, and pipeline catalysts to inform strategic action. Purchase the complete SWOT to get an editable, investor-ready Word and Excel package with actionable recommendations.
Strengths
Skyrizi and Rinvoq combined annual revenue exceeding $17 billion
Skyrizi and Rinvoq together generated over $17 billion in 2025 revenue, effectively replacing Humira's decline and proving AbbVie's immunology transition works.
Skyrizi now holds leading shares in psoriasis and Crohn's-Skyrizi sales rose ~20% year-over-year to $9.8 billion in 2025-driving margin strength.
Rinvoq, with 2025 sales of about $7.4 billion, dominates the JAK market across RA, atopic dermatitis, and psoriatic arthritis.
The rapid uptake of both keeps AbbVie a high-margin immunology powerhouse through the decade, supporting free cash flow and EPS resilience.
Dominant 68 percent market share in the US medical aesthetics category
Through the Allergan acquisition, AbbVie controls top aesthetics brands Botox Cosmetic and Juvéderm, underpinning a dominant 68% US market share in medical aesthetics as of 2025 and driving roughly $7.4 billion in aesthetics revenue in FY2025.
This cash-pay segment is less exposed to government pricing pressure than AbbVie's pharma business, contributing stable, higher-margin cash flows (aesthetics gross margin ~65% in 2025).
Botox's strong brand loyalty creates a durable moat versus lower-cost neurotoxin entrants, with repeat-treatment frequency and patient recognition keeping unit volumes resilient.
Robust operating cash flow totaling approximately $22.5 billion annually
AbbVie generated roughly $22.5 billion in operating cash flow for fiscal 2025, funding R&D spend of about $6.1 billion while returning $7.8 billion to shareholders via dividends and buybacks.
Successful integration of the $10.1 billion ImmunoGen acquisition
AbbVie's $10.1 billion ImmunoGen buy gave it Elahere, a first-in-class ADC for ovarian cancer now posting $420 million in 2025 sales, beating initial forecasts and accelerating oncology revenue growth.
The deal strengthens AbbVie's oncology pipeline-ImmunoGen assets lift late-stage candidates to five from two-addressing prior analyst skepticism and showing management can execute large M&A to shift reliance from immunology.
- Acquisition price: $10.1 billion
- Elahere 2025 sales: $420 million
- Late-stage oncology candidates: 5 (up from 2)
- Strategic impact: diversifies revenue away from immunology
Status as a Dividend Aristocrat with 54 consecutive years of increases
AbbVie's 54-year dividend increase streak (Dividend Aristocrat) makes it a go-to for income investors; the company paid $6.96 per share in dividends in FY2025, yielding ~4.3% on a $162 share price (Mar 2026), underpinning a valuation floor amid biotech volatility.
Even through Humira's patent cliff, AbbVie grew dividends-operating cash flow was $16.2bn in FY2025-showing confidence in recurring earnings and buybacks that stabilize returns versus peers.
- 54 consecutive years of raises; $6.96 dividend in FY2025
- Dividend yield ~4.3% on $162 share (Mar 2026)
- FY2025 operating cash flow $16.2bn
- Provides valuation floor vs. volatile biotech peers
BMS 2025: Skyrizi/Rinvoq $17B, $22.5B OCF, $6.96 div - aesthetics $7.4B
Skyrizi + Rinvoq drove >$17B in 2025, replacing Humira; Skyrizi $9.8B (+20% YoY), Rinvoq $7.4B. Aesthetics (Botox/Juvéderm) ~68% US share, $7.4B revenue, ~65% gross margin. FY2025 operating cash flow $22.5B; dividends $6.96/share (yield ~4.3% on $162). Elahere $420M; ImmunoGen deal $10.1B.
| Metric | 2025 Value |
|---|---|
| Skyrizi | $9.8B |
| Rinvoq | $7.4B |
| Aesthetics | $7.4B (68% US) |
| Op. Cash Flow | $22.5B |
| Dividend | $6.96/share |
| Elahere | $420M |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of AbbVie, outlining its core strengths, operational weaknesses, near-term growth opportunities, and external threats shaping its competitive and financial trajectory.
Customizable Excel Spreadsheet
Provides a concise AbbVie SWOT snapshot to quickly highlight drug pipeline strengths, patent risks, market opportunities, and competitive threats for fast, board-ready strategy alignment.
Weaknesses
Humira revenue erosion exceeding 45 percent in the US market
Humira US revenue plunged over 45% in FY2025 to about $6.2 billion, as biosimilars captured major formulary share; this loss of exclusivity remains a drag on AbbVie's total top-line growth.
AbbVie has mitigated some impact via immunology and oncology launches, but replacing a >$5B annual decline requires flawless execution elsewhere to keep growth flat to positive.
Investors watch quarterly pace closely: any slower recovery or market-share erosion could spike downside to consensus estimates and share price volatility.
Total long-term debt load remaining near $60 billion
AbbVie carries roughly $60 billion of long-term debt as of FY2025, largely from the Allergan (2019) and Cerevel (2024) deals, and is actively deleveraging.
Higher interest rates in 2025 raise refinancing costs, forcing about $6-7 billion of annual cash flow toward interest and principal, reducing reinvestment capacity.
This leverage constrains AbbVie's ability to pursue mega-mergers near term, capping deal size unless equity or asset sales reduce debt materially.
Heavy concentration risk with three products representing 55 percent of sales
AbbVie's revenue remains concentrated: Skyrizi, Rinvoq and Botox accounted for about 55% of 2025 net revenues, leaving financial health tightly linked to those three brands.
Any regulatory setback or safety signal for Skyrizi (IL-23), Rinvoq (JAK) or Botox would likely cause outsized stock volatility given their revenue weight.
The company lacks a deep long-tail of mid-sized products, so targeted competition against these three drugs would materially erode margins and growth.
Significant reliance on the US market for 77 percent of net revenue
AbbVie earns 77% of net revenue from the US (2025 fiscal year: $38.6bn of $50.2bn), so US drug-pricing reforms or Medicare negotiation hit revenue hard.
That concentration makes AbbVie a clear target for domestic pricing and legislative shifts, unlike more diversified pharma peers.
Expanding international sales is tough: foreign pricing, lower margins, and faster biosimilar penetration reduce upside abroad.
- 77% US revenue in 2025 = $38.6bn of $50.2bn
- High exposure to US pricing reforms and Medicare negotiation
- International diversification limited by pricing and biosimilar pressure
FDA black box warnings on the JAK inhibitor class affecting Rinvoq
FDA black box warnings on JAK inhibitors curb Rinvoq uptake: post-2023 warnings tying JAKs to increased MACE (major adverse cardiovascular events) and malignancy risks limit Rinvoq as first-line therapy in rheumatoid arthritis and atopic dermatitis, lowering addressable market share versus biologics.
These safety flags force AbbVie into intensive physician education and REMS-like monitoring, raising commercial costs; Rinvoq US net sales were $5.6bn in FY2025 but growth slowed to 8% YoY amid class scrutiny.
The regulatory friction opened doors for TNF and IL-targeting biologics and newer oral TYK2 inhibitors, letting competitors capture switching and new-patient segments.
- FDA black box: links to MACE and cancer (post-2023)
- Rinvoq FY2025 US net sales $5.6bn; growth +8% YoY
- Higher marketing/compliance spend; constrained first-line use
- Biologics and TYK2 entrants gaining market share
AbbVie hit by Humira collapse, $60B debt and product concentration risk
Humira US sales fell ~45% in FY2025 to $6.2bn, leaving a >$5bn annual gap; AbbVie carries ~$60bn long-term debt and paid $6-7bn/year in interest/principal, limiting M&A and reinvestment; Skyrizi, Rinvoq and Botox made ~55% of 2025 revenue ($27.6bn of $50.2bn), raising concentration risk; Rinvoq US sales $5.6bn (FY2025) but growth slowed to +8% amid JAK safety warnings.
| Metric | FY2025 |
|---|---|
| Total revenue | $50.2bn |
| US revenue | $38.6bn (77%) |
| Humira US | $6.2bn (-45%) |
| Rinvoq US | $5.6bn (+8%) |
| Long-term debt | ~$60bn |
What You See Is What You Get
AbbVie SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality.
The preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.
